H.R. 6227 · 118th Congress
Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023
- Stage
- In committee
- Sponsor
- David Schweikert
- Introduced
- 2023-11-03
- Latest action
- 2023-11-10 · Referred to the Subcommittee on Health.
Summary
Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023
This bill expands the priority-review voucher program for tropical diseases to include coccidioidomycosis (also known as Valley fever). A voucher entitles the holder to have a future new drug or biological product application acted upon by the Food and Drug Administration within six months.